Selecta Biosciences

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

I attended Selecta Biosciences' management presentation and breakout Q&A session at the recent annual Jefferies healthcare investor conference.

Selecta Biosciences: Key Takeaways From Jefferies Management Meeting

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q1 2019 Results - Earnings Call Transcript

As of late, it has definitely been a great time to be an investor in Selecta Biosciences.

Will Selecta Biosciences Continue to Surge Higher?

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q4 2018 Results - Earnings Call Transcript

News for Selecta Biosciences Stock (SELB)